Latest Breaking News On - Healthquest capital - Page 18 : comparemela.com

Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis

Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis News provided by Share this article Share this article NEWTON, Mass., Feb. 23, 2021 /PRNewswire/ Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced publication of a position paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Pancreas Committee recommending the use of RELiZORB ® (immobilized lipase cartridge), a first-of-its-kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase. Their recommendation further reinforces the clinical benefits of RELiZORB (immobilized lipase cartridge) in patients with fat malabsorption conditions beyond cystic fibrosis.

United statesDan orlandoNutrition pancreas committeeAmerican society for pediatric gastroenterologyAlcresta therapeutics incTherapeutics incPancreas committeeAlcresta therapeuticsNorth american societyPediatric gastroenterologyCystic fibrosisEric firstMedical managementChronic pancreatitisPosition paperNutrition pancreas

Austin startup Everlywell adds HealthQuest Capital as investor

Austin startup Everlywell adds HealthQuest Capital as investor
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

Garheng kongHealthquest capitalGinkgo bioworksIntrivo diagnosticsஹெல்த்‌க்வெஸ்ட் மூலதனம்

Health tech giant Hillrom to acquire Seattle startup Bardy Diagnostics for $375M

Health tech giant Hillrom to acquire Seattle startup Bardy Diagnostics for $375M January 19, 2021 at 10:31 am Dr. Gust Bardy, founder of Bardy Diagnostics. (Bardy Photo) Hillrom, a publicly-traded medical device and digital health company based in Chicago, will pay $375 million to acquire Seattle startup Bardy Diagnostics. Founded in 2013, Bardy set out to change the way medical professionals monitor heart conditions with a non-invasive cardiac monitor patch that helps detect arrhythmia. The Carnation Ambulatory Monitor, or CAM for short, is designed to be worn comfortably for approximately a week, with the goal of improving patient compliance. It uses a unique circuit design and algorithms to process P-wave recording. Bardy claims that its device captures clearer and more accurate heart rhythms than competing electrocardiography (ECG) monitors.

United statesJohn groetelaarsSv health investorsBoston scientificHealth enterprise partnersUniversity of washingtonSeattle institute for cardiac researchCameron healthRiver cities capital fundRex health venturesGust bardyBardy photoCarnation ambulatory monitorNew providenceAdvancing connected careRiver cities capital

Daily Crunch: WhatsApp responds to privacy backlash – TechCrunch

WhatsApp delays enforcement of a controversial privacy change, Apple may get rid of the Touch Bar in future MacBooks and Bumble files to go public. This is your Daily Crunch for January 15, 2021. The big story: WhatsApp responds to privacy backlash Earlier this month, WhatsApp sent users a notification asking them to consent to […]

Jeff lawsonTracy chouBlock partyTouch barDaily crunchMacbook prosHealthquest capitalTop hatFountainhead pressExtra crunchஜெஃப் லாசன்சுவடு ச ouதொகுதி கட்சிதொடு மதுக்கூடம்தினசரி நெருக்கடிமேக்புக் ப்ரோஸ்

Everlywell raises $75M from HealthQuest Capital following its recent $175M Series D round – TechCrunch

Everlywell raises $75M from HealthQuest Capital following its recent $175M Series D round At-home health testing kit startup Everlywell has raised $75 million, following the close of the $175 million Series D it announced in December. The new funding comes from HealthQuest Capital, and sees the fund’s founder and managing partner Dr. Garheng Kong join the company’s board of directors. Everlywell will use proceeds of this financing to provide liquidity to existing investors, so the startup’s $1.3 billion valuation from December still holds. HealthQuest Capital’s investment portfolio has a heavy focus on commercialization of diagnostics businesses, and the company’s parent obviously has a board network of partners including hospitals and healthcare payers, both of which are going to be very strategically useful to Everlywell as it looks to scale its business on the enterprise side.

Garheng kongHealthquest capitalCquest capitalJulia cheekஹெல்த்‌க்வெஸ்ட் மூலதனம்தேடலை மூலதனம்ஜூலியா கன்னம்